Drugs for the management of osteoporosis: A review

Revista Brasileira de Reumatologia

Volumn 51, Issue 4, 2011, Pages 365-382

  Khajuria, Deepak Kumar ^a   Razdan, Rema ^a   Mahapatra, D Roy ^b  

^a AL AMEEN COLLEGE OF PHARMACY   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Antiresorptive agents; Bisphosphonates; Osteoblast; Osteoporosis; Postmenopausal

Indexed keywords

ALENDRONIC ACID; BALICATIB; BETA CATENIN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CATHEPSIN K; COLECALCIFEROL; DENOSUMAB; DICKKOPF 1 PROTEIN; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; IBANDRONIC ACID; MONOCLONAL ANTIBODY; ODANACATIB; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; PROTEIN TYROSINE KINASE; RALOXIFENE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RELACATIB; RISEDRONIC ACID; SARACATINIB; SCLEROSTIN; STRONTIUM RANELATE; TIBOLONE; UNINDEXED DRUG; WNT PROTEIN; ZOLEDRONIC ACID;

BONE FRAGILITY; BONE MASS; BONE STRUCTURE; BONE TISSUE; BREAST CANCER; CONTROLLED CLINICAL TRIAL (TOPIC); DIET SUPPLEMENTATION; DIGITAL RADIOGRAPHY; DISEASE PREDISPOSITION; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; ESOPHAGUS DISEASE; ESTROGEN THERAPY; FOOD COMPOSITION; FOOD INTAKE; FRACTURE; FRAGILITY FRACTURE; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; INDIA; INHIBITION KINETICS; JAW OSTEONECROSIS; KIDNEY DISEASE; MEDICAL DECISION MAKING; NONHUMAN; NONSPINAL FRACTURE; NONVERTEBRA FRACTURE; NONVERTEBRAL FRACTURE; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; VASCULAR DISEASE; VERTEBRA FRACTURE;

DIPHOSPHONATES; HUMANS; OSTEOPOROSIS;

EID: 79960580658     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Lirani-Galvão AP, Lazaretti-Castro M. Physical approach for prevention and treatment of osteoporosis. Arq Bras Endocrinol Metabol 2010; 54 (2):171-8.
2. Martin RM, Correa PH. Bone quality and osteoporosis therapy. Arq Bras Endocrinol Metabol 2010; 54 (2):186-99.
3. Osteoporosis in Men, http://www.niams.nih.gov/health_info/bone/osteoporosis/men.pdf, 2010.
4. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, la Croix AZ et al. For the Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003; 290:1729-38.
5. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007; 357:905-16.
6. Muchmore DB. Raloxifene: A Selective Estrogen Receptor Modulator (SERM) with Multiple Target System Effects. The Oncologist.2000; 5 (5): 388-392.
7. De Paula FJ, Rosen CJ. Developing drugs to treat osteoporosis: lessons learned? Expert Opin Pharmacother 2010; 11:867-9.
8. Cranney A, Guyatt G, Griffth L, Wells G, Tugwell P, Rosen C et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23:570-8.
9. Sambrook PN, Ebeling P. Osteonecrosis of the jaw. Curr Rheumatol Rep 2008; 10:97-101.
10. World Population Prospects: The 2008 Revision Population Database. United Nations Population Division. http://esa.un.org/unpp, 2010.
11. Malhotra N, Mithal A. Osteoporosis in Indians. Indian J Med Res. 2008; 127:263-8.
12. The Asian Audit Epidemiology, costs and burden of osteoporosis in Asia 2009. http://www.iofbonehealth.org/download/osteofound/flemanager/publications/pdf/Asian-audit-09/2009-Asian_Audit. pdf, 2010.
13. Jha RM, Mithal A, Malhotra N, Brown EM. Pilot case-control investigation of risk factors for hip fractures in the urban Indian population. BMC Musculoskeletal Disorders 2010; 11:49.
14. Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA et al. Global vitamin D status and de terminants of hypovitaminosis D. Osteoporos Int 2009; 20 (11):1807-20.
15. Bhatia V. Dietary calcium intake- a critical reappraisal. Indian J Med Res 2008; 127: 269-273.
16. Vitamin D. Calcium: Update Dietary Reference Intakes. http://www.hc-sc.gc.ca/fn-an/nutrition/vitamin/vita-d-eng.php
17. Pande K.C, Johansen K.B, Helboe AB. Digital X-ray Radiogrammetry: establishment and comparison of Indian female and male normative reference data. J Bone Miner Res 2001; 16 (Suppl 1): M087.
18. Action Plan Osteoporosis. The Osteoporosis Society of India. http://www.iofbonehealth.org/download/osteofound/flemanager/policy_advocacy/pdf/action_plan_osteo.pdf.
19. Cawston TE, Young DA. Proteinases involved in matrix turnover during cartilage and bone breakdown. Cell Tissue Res 2010; 339:221-35.
20. Assessment of fracture risk and its application to screening for postmenopaus al osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843:1-129.
21. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporos Int 1998; 8(4):S1-S88.
22. th Edition, Springer New York, 2008. http://www.springerlink.com/content/q1326418384m29t7/fulltext.pdf, 2010.
23. Riggs BL, Melton LJ, O'Fallon WM. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture effcacy. Bone 1996; 18:197S-201S.
24. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C et al. Markers of bone resorption predicts hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996; 11:1531-8
25. Miller PD, Baran DT, Bilezikian JP, Greenspan SL, Lindsay R, Riggs BL et al. Practical clinical application of biochemical markers of bone turnover: Consensus of an expert panel. J Clin Densitom 1999; 2:323-42.
26. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003; 111:1120-2.
27. Bord S, Ireland DC, Beavan SR, Compston JE. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 2003; 32:136-41.
28. Heaney RP, Recker RR, Saville PD. Menopause changes in calcium balance performance. J Lab Clin Med 1978; 92:953-63.
29. Mc-Kane WR, Khosla S, Burritt MF, Kao PC, Wilson DM, Ory SJ et al. Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmenopause - a clinical research center study. J Clin Endocrinol Metab 1995; 80:3458-64.
30. Gennari C, Agnusdei D, Nardi P, Civitelli R. Estrogen preserves a normal intestinal responsiveness to 1,25-dihydroxyvitamin D3 in oophorectomized women. J Clin Endocrinol Metab 1990; 71:1288-93.
31. Riggs BL, Khosla S, Melton LJ. A unitary model for involutional osteoporosis:estrogen defciency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998; 13:763-73.
32. Cosman F, Nieves J, Horton J, Shen V, Lindsay R. Effects of estrogen on response to edetic acid infusion in postmenopausal osteoporotic women. J Clin Endocrinol Metab 1994; 78:939-43.
33. Ernst M, Heath JK, Rodan GA. Estradiol effects on proliferation, messenger ribonucleic acid for collagen and insulin-like growth factor-I, and parathyroid hormone-stimulated adenylate cyclase activity in osteoblastic cells from calvariae and long bones. Endocrinology 1989; 125:825-33.
34. Oursler MJ, Cortese C, Keeting PE, Anderson MA, Bonde SK, Riggs BL et al. Modulation of transforming growth factor-b production in normal human osteoblast-like cells by 17b-estradiol and parathyroid hormone. Endocrinology 1991; 129:3313-20.
35. Pacifci R. T cells and post menopausal osteoporosis in murine models. Arthritis Res Ther 2007; 9:102.
36. Robbie-Ryan M, Pacifici R, Weitzmann MN. IL-7 drives T cellmediated bone loss following ovariectomy. Ann N Y Acad Sci 2006; 1068:348-51.
37. Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, Yang X et al. IFN-g stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 2007; 117:122-32.
38. Rauner M, Sipos W, Pietschmann P. Osteoimmunology. Int Arch Allergy Immunol 2007; 143:31-48.
39. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992; 327:1637-42.
40. Bischoff HA, Stahelin HB, Dick W, Akos R, Knecht M, Salis C et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 2003; 18:343-51.
41. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003; 326:469.
42. Twiss IM, Pas O, Ramp-Koopmanschap W, den Hartigh J, Vermeij P. The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium. J Bone Miner Res 1999; 14:784-91.
43. Waalen J. Current and emerging therapies for the treatment of osteoporosis. J Exp Pharmacol 2010; 2:121-34.
44. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83:1032-45.
45. Watts N.B, Diab D.L. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010; 95:1555-65.
46. Papapetrou PD. Bisphosphonate-associated adverse events. Hormones 2009; 8(2):96-110.
47. Edwards BJ, Gounder M, Mc-Koy JM. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 2008; 9:1166-72.
48. Bamias A, Kastritis E, Bamia C. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23:8580-7.
49. Marx RE. 2003 Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61:1238-1239.
50. Khosla S, Burr D, Cauley J. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone Na Mineral Research. Editorial. J Bone Min Res 2007; 22:1479-91.
51. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws, September 25, 2006 http://www.aaoms.org/docs/position_papers/osteonecrosis.pdf.
52. Ruggiero S, Gralow J, Marx RE. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006; 2:7-14.
53. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate- induced osteonecrosis: risk factors,prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65:2397-410.
54. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al. Once yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356:1809-22.
55. Heckhert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fbrillation in women. Arch Intern Med 2008; 168:826-31.
56. Sorensen HT, Christensen S, Mehnert F, Pedersen L, Chapurlat RD, Cummings SR et al. Use of bisphosphonates among women and risk of atrial fbrillation and futter: population based case-control study. BMJ 2008; 336:813-6.
57. Update of safety review follow-up to the October 1, 2007, Early communication about the ongoing safety review of bisphosphonates (http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm).
58. Odvina CV, Zerwekh JE, Rao ES, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90:1294-301.
59. Visekruna M, Wilson D, McKienan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008; 93:2948-52.
60. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000; 15:613-20.
61. Visekruna M, Wilson D, Mc-Kiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008; 93:2948-52.
62. Armamento-Villareal R, Napoli N, Diemer K, Watkins M, Civitelli R, Teitelbaum S et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tiss Int 2009; 85:37-44.
63. Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am 2009; 91:2556-61.
64. Chesnut CH, Azria M, Silverman S, Engelhardt M, Olson M, Mindeholm L. Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos Int 2008; 19:479-91.
65. Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif Tissue Int 1994; 55:82-6.
66. Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000; 109:267-76.
67. Chesnut CH, Majumdar S, Newitt DC, Shields A, Van Pelt J, Laschansky E et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. J Bone Miner Res 2005; 20:1548-61.
68. Ljunghall S, Gardsell P, Johnell O, Larsson K, Lindh E, Obrant K et al. Synthetic human calcitonin in postmenopausal osteoporosis: a placebocontrolled, double-blind study. Calcif Tissue Int 1991; 49:17-9.
69. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282:637-45.
70. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001; 65:125-34.
71. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287:847-57.
72. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefts of estrogen plus progestin in healthy postmenopausal women: principal results from the Womens Health Initiative randomized controlled trial. JAMA 2002; 288:321-33.
73. Stefanick ML. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med 2005; 118(12):64-73.
74. Beardsworth SA, Kearney CE, Purdie DW. Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two-year randomised controlled trial. Br J Obstet Gynaecol 1999; 106:678-83.
75. Berning B, Kuijk CV, Kuiper JW, Bennink HJ, Kicovic PM, Fauser BC. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. Bone 1996; 19:395-9.
76. Roux C, Pelissier C, Fechtenbaum J, Loiseau-Peres S, Benhamou CL. Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporos Int 2002; 13:241-8.
77. Pleiner-Duxneuner J, Zwettler E, Paschalis E, Roschger P, Nell-Duxneuner V, Klaushofer K. Treatment of osteoporosis with parathyroid hormone and teriparatide. Calcif Tissue Int 2009; 84:159-70.
78. Trevisani VF, Riera R, Imoto AM, Saconato H, Atallah AN. Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review. Sao Paulo Med J 2008; 126:279-84.
79. Vestergaard P, Jorgensen NR, Mosekilde L, Schwarz P. Effects of parathyroid hormone alone or in combination with anti-resorptive therapy on bone mineral density and fracture risk - a meta-analysis. Osteoporos Int 2007; 18:45-57.
80. Neuprez A, Hiligsmann M, Scholtissen S, Bruyere O, Reginster JY. Strontium ranelate: the frst agent of a new therapeutic class in osteoporosis. Adv Ther 2008; 25:1235-56.
81. O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 2006; 3:CD005326.
82. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C et al. Strontium ranelate: dose- dependent effects in established postmenopausal vertebral osteoporosis a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002; 87:2060-6.
83. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350:459-68.
84. Reginster J Y, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of non-vertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90:2816-22.
85. Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled Prevos trial. Osteoporos Int 2002; 13:925-31.
86. Reginster J Y, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML et al. Effects of long-term strontium ranelate treatment on the risk of non-vertebral and vertebral fractures in postmenopausal osteoporosis: results of a fve-year, randomized, placebo-controlled trial. Arthritis Rheum 2008; 58:1687-95.
87. US Food and Drug Administration, FDA labeling information -Prolia (denosumab). FDA website, http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125320s0000lbl.pdf, 2010.
88. European Medicines Agency (EMA). European Public Assessment Report - Prolia. EMA website [online], http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/001120/WC500093526.pdf, 2010.
89. Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009; 24:182-95.
90. Cummings SR, San Martin J, Mc-Clung RMR, Siris ES, Eastell R, Reid IR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756-65.
91. Peroni A, Zini A, Braga V, Colato C, Adami S, Girolomoni G. Drug-induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol 2008; 59:125-9.
92. Kumar S, Dare L, Vasko-Moser JA, James IE, Blake SM, Rickard DJ et al. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 2007; 40:122-31.
93. Horne WC, Sanjay A, Bruzzaniti A, Baron R. The role(s) of Src kinase and Cbl proteins in the regulation of osteoclast differentiation and function. Immunol Rev 2005; 208:106-25.
94. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991; 64:693-702.
95. Hannon RA, Clack G, Rimmer M, Swaisland A, Lockton JA, Finkelman RD et al. Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple ascending dose phase I trial. J Bone Miner Res 2010; 25(3):463-71.
96. Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinol 2007; 148:2635-43.
97. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M et al. Increased bone density in sclerosteosis is due to the defciency of a novel secreted protein (SOST). Hum Mol Genet 2001; 10:537-43.
98. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C et al. Identifcation of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002; 39:91-7.
99. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009; 24:578-88.
100. Betts AM, Clark TH, Yang J, Treadway JL, Li M, Giovanelli MA et al. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther 2010; 333:2-13.
101. Ominsky MS, Vlasseros F, Jolette J, Smith S Y, Stouch B, Doellgast G et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010; 25(5):948-59.
102. Kulkarni NH, Onyia JE, Zeng Q, Tian X, Liu M, Halladay DL et al. Orally bioavailable GSK-3alpha/ beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res 2006; 21:910-20.
103. Hoeppner LH, Secreto FJ, Westendorf JJ. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 2009; 13:485-96.